Novartis ends Diovan, Lotrel sales contract
Executive Summary
Novartis is bolstering internal resources for the antihypertensives Diovan and Lotrel following termination of sales contract with PDI, company says. Current promotion by PDI of valsartan and amlodipine/benazepril with 300 reps will end effective March 16, PDI announces Feb. 18. Novartis had already scaled back the contract from 518 reps (1"The Pink Sheet" Jan. 5, 2004, In Brief)...
You may also be interested in...
Novartis reduces PDI sales contract
Novartis reduces its contract with PDI for next year to 300 reps, down from 518 in 2003. The contract sales organization will support the sale of the antihypertensives Diovan and Lotrel but will no longer sell Lotensin, which will go off patent in February. Novartis upped its support of its hypertension drugs with the launch of a blood pressure awareness campaign in August (1"The Pink Sheet" Aug. 18, 2003, In Brief)...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.